Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:ORKA NASDAQ:PVLA NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$6.00-3.3%$3.86$1.60▼$15.04$162.59M2566,371 shs348,429 shsORKAOruka Therapeutics$25.56+13.0%$15.85$5.49▼$31.13$957.22M-0.29274,697 shs863,675 shsPVLAPalvella Therapeutics$72.50-3.1%$53.41$11.17▼$76.43$801.85M-0.13109,170 shs241,497 shsTYRATyra Biosciences$13.79+1.1%$12.06$6.42▼$29.60$734.70M1.11285,766 shs61,332 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+4.36%+52.08%+59.08%+137.40%-44.71%ORKAOruka Therapeutics+9.92%+21.43%+43.10%+60.70%-17.81%PVLAPalvella Therapeutics+5.84%+18.38%+36.04%+177.84%+7,484,999,900.00%TYRATyra Biosciences+1.94%+1.56%+12.37%+33.11%-37.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$6.00-3.3%$3.86$1.60▼$15.04$162.59M2566,371 shs348,429 shsORKAOruka Therapeutics$25.56+13.0%$15.85$5.49▼$31.13$957.22M-0.29274,697 shs863,675 shsPVLAPalvella Therapeutics$72.50-3.1%$53.41$11.17▼$76.43$801.85M-0.13109,170 shs241,497 shsTYRATyra Biosciences$13.79+1.1%$12.06$6.42▼$29.60$734.70M1.11285,766 shs61,332 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+4.36%+52.08%+59.08%+137.40%-44.71%ORKAOruka Therapeutics+9.92%+21.43%+43.10%+60.70%-17.81%PVLAPalvella Therapeutics+5.84%+18.38%+36.04%+177.84%+7,484,999,900.00%TYRATyra Biosciences+1.94%+1.56%+12.37%+33.11%-37.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.44Hold$9.8063.22% UpsideORKAOruka Therapeutics 2.83Moderate Buy$42.0064.32% UpsidePVLAPalvella Therapeutics 2.92Moderate Buy$75.504.14% UpsideTYRATyra Biosciences 2.88Moderate Buy$31.86131.10% UpsideCurrent Analyst Ratings BreakdownLatest ANRO, ORKA, TYRA, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$66.00 ➝ $90.0010/8/2025ANROAlto NeuroscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ORKAOruka TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PVLAPalvella TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TYRATyra BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025PVLAPalvella TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$120.0010/2/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $80.009/29/2025ANROAlto NeuroscienceChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.009/29/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/27/2025ANROAlto NeuroscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ORKAOruka TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/APVLAPalvella TherapeuticsN/AN/AN/AN/A$5.58 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.78N/AN/AN/AN/A-31.22%-29.49%11/6/2025 (Estimated)Latest ANRO, ORKA, TYRA, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025TYRATyra Biosciences-$0.50N/AN/AN/AN/AN/A8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/14/2025Q2 2025TYRATyra Biosciences-$0.53-$0.47+$0.06-$0.47N/AN/A8/13/2025Q2 2025ANROAlto Neuroscience-$0.57-$0.65-$0.08-$0.65N/AN/A8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1818.4318.43ORKAOruka TherapeuticsN/A27.4227.42PVLAPalvella TherapeuticsN/A7.677.67TYRATyra BiosciencesN/A21.9421.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AORKAOruka Therapeutics56.44%PVLAPalvella Therapeutics40.11%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.13%ORKAOruka Therapeutics24.69%PVLAPalvella Therapeutics20.50%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.08 million24.06 millionN/AORKAOruka TherapeuticsN/A37.45 million28.20 millionN/APVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ATYRATyra Biosciences2053.30 million45.20 millionOptionableANRO, ORKA, TYRA, and PVLA HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 9 at 2:17 AM | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 9 at 2:15 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Raised to "Hold" at Wall Street ZenOctober 4, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Sold by Canaan Partners XI LLCSeptember 30, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Downgraded to Sell Rating by Wall Street ZenSeptember 27, 2025 | marketbeat.comAdvanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsightSeptember 25, 2025 | finance.yahoo.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from BrokeragesSeptember 15, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 15, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Acquired by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comTyra Biosciences price target raised to $36 from $30 at OppenheimerSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRASeptember 9, 2025 | marketbeat.comNMIBC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market PotentialSeptember 8, 2025 | theglobeandmail.comWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4, 2025 | msn.comTyra Biosciences management to meet with OppenheimerSeptember 4, 2025 | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3, 2025 | msn.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences Announces Participation at Upcoming Investor EventsAugust 20, 2025 | prnewswire.comDelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 20, 2025 | finanznachrichten.deFGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 19, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANRO, ORKA, TYRA, and PVLA Company DescriptionsAlto Neuroscience NYSE:ANRO$6.00 -0.21 (-3.32%) Closing price 03:59 PM EasternExtended Trading$5.99 -0.01 (-0.23%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Oruka Therapeutics NASDAQ:ORKA$25.56 +2.94 (+13.00%) Closing price 03:59 PM EasternExtended Trading$25.70 +0.14 (+0.53%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Palvella Therapeutics NASDAQ:PVLA$72.50 -2.35 (-3.14%) As of 03:47 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Tyra Biosciences NASDAQ:TYRA$13.78 +0.16 (+1.14%) Closing price 03:59 PM EasternExtended Trading$13.80 +0.02 (+0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
